EC Number   |
Expression |
Reference |
|---|
    3.3.2.10 | down |
high glucose and high concentration of reactive oxygen species suppresses sEH mRNA and protein expression in Hep-3B cells. Inhibition of NADPH oxidase inhibits the decrease in sEH by high glucose and the addition of hydrogen peroxide to Hep3B cells suppresses the expression of sEH |
708324 |
| 3.3.2.10 | down |
high glucose levels suppress sEH expression in diabetic mouse liver, which is reversible by insulin |
708324 |
| 3.3.2.10 | down |
relative expression of sEH is lower at both the mRNAand protein levels in HepG2 cells than in other cells with the same amount of total RNA or protein loaded. Transcription factor SP-1 is involved in the decrease in the transcription of sEH as a result of DNA methylation in HepG2 cells, which might contribute to epigenetic mechanism-induced carcinogenesis in hepatocytes |
714311 |
| 3.3.2.10 | down |
sEH is suppressed by estrogen |
709248 |
| 3.3.2.10 | down |
there is a significant reduction in protein expression in renal and liver malignant neoplasms compared to healthy tissue |
731877 |
| 3.3.2.10 | up |
enzyme expression increases 3-28 days after pilocarpine-induced status epilepticus |
731562 |
| 3.3.2.10 | up |
enzyme expression is increased in patients with glomerulonephritis |
731107 |
| 3.3.2.10 | up |
expression of sEH is significantly increased on day 7, 14, 21 and 28 after pilocarpine-induced status epilepticus |
-, 753120 |
| 3.3.2.10 | up |
homocysteine significantly upregulates enzyme mRNA expression. PPARgamma activation is linked to enzyme expression in human endothelial cells. Angiotensin-II treatment of HUVECs results in an over 2fold increase in mRNA expression |
731877 |
| 3.3.2.10 | up |
pharmacological induction of sEH by exposure to peroxisome-proliferating activated receptor alpha ligands like clofibrate, tiadenol, or acetylsalicylic acid |
708022 |
